CIGB-247 vaccine breaks immunological tolerance to the vascular endothelial growth factor in mice, rats, rabbits and non-human primates, without disturbing physiologic angiogenic processes
CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human vascular endothelial growth factor (VEGF) as antigen in combination with the oil-free adjuvant VSSP (very small sized proteoliposomes of Neisseria meningitidis outer membrane). The vaccine was designed to affect tumor n...
Main Authors: | Yanelys Morera, Mónica Bequet, Marta Ayala, Jorge V Gavilondo, Jorge Castro, Pedro Puente, Julio Ancízar, José Suarez, Javier Sanchez, Karelia Cosme, Dania Bacardí, Boris E Acevedo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elfos Scientiae
|
Series: | Biotecnología Aplicada |
Subjects: | |
Online Access: | http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522012000200008&lng=en&tlng=en |
Similar Items
-
Terapia angiogénica en el tratamiento de la cardiopatía isquémica Angiogenic therapy in the ischemic cardiopathy treatment
by: Alejandro Villar Inclán
Published: (2007-09-01) -
Preclinical safety testing of the Quimi-Hib(r) vaccine adjuvanted with aluminum phosphate during product development
by: Dania Bacardí, et al. -
La señalización de angiopoyetinas a través de receptores TIE estimula la diferenciación de células troncales neurales obtenidas desde médula espinal de ratón
by: Silva Pinto, Pablo Roberto
Published: (2013) -
Uso de terapia antifactor de crecimiento vascular endotelial en patología corneal
by: Tomás Rojas, et al.
Published: (2014-07-01) -
Mecanismos antiangiogénicos de calreticulina de Trypanosoma cruzi
by: López Bartolucci, Nandy Carolina
Published: (2012)